KF17837 is an A2 adenosine receptor antagonist in vivo - PubMed (original) (raw)
Comparative Study
. 1993 Dec;267(3):1304-10.
Affiliations
- PMID: 8263794
Comparative Study
KF17837 is an A2 adenosine receptor antagonist in vivo
E K Jackson et al. J Pharmacol Exp Ther. 1993 Dec.
Abstract
The goal of this study was to determine whether (E)-1,3-dipropyl-7-methyl-8-(3,4-dimethoxystyryl)xanthine (KF17837) is a useful pharmacological probe for investigating in the rat the in vivo physiological roles of A2 adenosine receptors. In anesthetized rats, bradycardic responses to N6-cyclopentyladenosine and hypotensive responses to 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamido adenosine (CGS21680C) were used to assess A1 receptor and A2 receptor activation, respectively. After obtaining control responses to N6-cyclopentyladenosine and CGS21680C, the rats received infusions of either vehicle or one of two dosage levels of KF17837, a compound recently demonstrated to be a potent and selective A2 receptor antagonist in vitro. KF17837 was infused for 4 hr and, at various times during the infusions, bradycardic and hypotensive responses to N6-cyclopentyladenosine and CGS21680C, respectively, were elicited. Infusion of either 10 or 30 micrograms kg-1 min-1 (2.4 or 7.4 mg kg-1 4 hr-1) of KF17837 did not significantly affect the bradycardic responses to N6-cyclopentyladenosine. By contrast, 10 micrograms kg-1 min-1 of KF17837 attenuated and 30 micrograms kg-1 min-1 of KF17837 nearly abolished hypotensive responses to CGS21680C. In a second study, pretreatment with KF17837 (30 micrograms kg-1 min-1) did not affect the hypotensive response to either PGI2 (3 micrograms kg-1 min-1) or acetylcholine (100 micrograms kg-1 min-1); however, it attenuated the hypotensive response to adenosine (300 micrograms kg-1 min-1). In a third study, hypotension was induced and maintained with an infusion of adenosine (300 micrograms kg-1 min-1).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- An experimental paradigm for investigating the role of endogenous adenosine/A1 receptor interactions in vivo.
Kuan CJ, Herzer WA, Jackson EK. Kuan CJ, et al. J Pharmacol Exp Ther. 1992 Nov;263(2):657-62. J Pharmacol Exp Ther. 1992. PMID: 1432696 - Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques.
Marston HM, Finlayson K, Maemoto T, Olverman HJ, Akahane A, Sharkey J, Butcher SP. Marston HM, et al. J Pharmacol Exp Ther. 1998 Jun;285(3):1023-30. J Pharmacol Exp Ther. 1998. PMID: 9618404 - Repeated administration of selective adenosine A1 and A2 receptor agonists in the spontaneously hypertensive rat: tolerance develops to A1-mediated hemodynamic effects.
Casati C, Monopoli A, Dionisotti S, Zocchi C, Bonizzoni E, Ongini E. Casati C, et al. J Pharmacol Exp Ther. 1994 Mar;268(3):1506-11. J Pharmacol Exp Ther. 1994. PMID: 8138961 - Adenosine receptor-mediated alterations in prostacyclin production and cardiac function in the isolated rabbit heart.
Cano C, Malik KU. Cano C, et al. J Pharmacol Exp Ther. 1992 May;261(2):660-8. J Pharmacol Exp Ther. 1992. PMID: 1578377 - CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity.
Hutchison AJ, Webb RL, Oei HH, Ghai GR, Zimmerman MB, Williams M. Hutchison AJ, et al. J Pharmacol Exp Ther. 1989 Oct;251(1):47-55. J Pharmacol Exp Ther. 1989. PMID: 2795469
Cited by
- Progress in the pursuit of therapeutic adenosine receptor antagonists.
Moro S, Gao ZG, Jacobson KA, Spalluto G. Moro S, et al. Med Res Rev. 2006 Mar;26(2):131-59. doi: 10.1002/med.20048. Med Res Rev. 2006. PMID: 16380972 Free PMC article. Review. - Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats.
Satoh S, Matsumura H, Suzuki F, Hayaishi O. Satoh S, et al. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5980-4. doi: 10.1073/pnas.93.12.5980. Proc Natl Acad Sci U S A. 1996. PMID: 8650205 Free PMC article. - Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo.
Mathoôt RA, Soudijn W, Breimer DD, Ijzerman AP, Danhof M. Mathoôt RA, et al. Br J Pharmacol. 1996 May;118(2):369-77. doi: 10.1111/j.1476-5381.1996.tb15412.x. Br J Pharmacol. 1996. PMID: 8735640 Free PMC article. - Pharmacokinetic modelling of the haemodynamic effects of the A2a adenosine receptor agonist CGS 21680C in conscious normotensive rats.
Mathôt RA, Cleton A, Soudijn W, IJzerman AP, Danhof M. Mathôt RA, et al. Br J Pharmacol. 1995 Feb;114(4):761-8. doi: 10.1111/j.1476-5381.1995.tb13270.x. Br J Pharmacol. 1995. PMID: 7773536 Free PMC article. - Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists.
Schindler CW, Karcz-Kubicha M, Thorndike EB, Müller CE, Tella SR, Ferré S, Goldberg SR. Schindler CW, et al. Br J Pharmacol. 2005 Mar;144(5):642-50. doi: 10.1038/sj.bjp.0706043. Br J Pharmacol. 2005. PMID: 15678095 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous